Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

• Автори: Karl-Ulrich Petry (Автор), Kaatje Bollaerts (Автор), Paolo Bonanni (Автор), Margaret Stanley (Автор), Rosybel Drury (Автор), Elmar Joura (Автор), Susanne K. Kjaer (Автор), Chris J. L. M. Meijer (Автор), Didier Riethmuller (Автор), Benoit Soubeyrand (Автор), Pierre Van Damme (Автор), Xavier Bosch (Автор)
• Формат: Книга
• Опубліковано: Taylor & Francis Group, 2018-07-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...